09.07.2012 - Spanish molecular diagnostics company Inbiomotion S.L. has raised €2m in a series A round.
The new investor, Ysios Capital, led the round. Fundacio Vila Casas and JVRisk Technologies also participated. Inbiomotion is a 2010 spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA). The firm develops biomarkers to predict bone metastasis from primary tumour biopsies, with its lead biomarker coding for an undisclosed nuclear protein. Inbiomotion, based in the Barcelona Science Park and founded by Roger Gomis, is carrying out a trial to validate the capacity of its marker to predict future bone metastasis using technology developed by IRB Barcelona. The investment raised will go to fund the validation of this marker through various clinical trials in Barcelona and England, and to advance development through regulatory approval. According to Inbiomotion, its biomarker has been validated with more than 900 patient samples in two different trials carried out with independent techniques (gene expression and immunohistochemistry), with a negative predictive value of 95%.
18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.